Avenell A, Gillespie W J, Gillespie L D, O'Connell D L
Health Services Research Unit, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, Scotland, UK, AB25 2ZD.
Cochrane Database Syst Rev. 2005 Jul 20(3):CD000227. doi: 10.1002/14651858.CD000227.pub2.
Vitamin D and related compounds have been used to prevent fractures.
To determine the effects of vitamin D or analogues, with or without calcium, in the prevention of fractures in older people.
We searched the Cochrane Bone, Joint and Muscle Trauma Group trials register, the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 1, 2005), MEDLINE, EMBASE, CINAHL, and reference lists of articles. Most recent search: March 2005.
Randomised or quasi-randomised trials comparing vitamin D or an analogue, alone or with calcium, against placebo, no intervention, or calcium, reporting fracture outcomes, in older people.
Two authors independently assessed trial quality, and extracted data. Data were pooled, where admissible, using the fixed-effect model, or random-effects model if the relative risks were heterogeneous.
Vitamin D alone showed no statistically significant effect on hip fracture (seven trials, 18,668 participants, RR 1.17, 95% CI 0.98 to 1.41), vertebral fracture (four trials, 5698 participants, RR (random effects) 1.13, 95% CI 0.50 to 2.55) or any new fracture (eight trials, 18,903 participants, RR 0.99, 95% CI 0.91 to 1.09). Vitamin D with calcium marginally reduced hip fractures (seven trials, 10,376 participants, RR 0.81, 95% CI 0.68 to 0.96), non-vertebral fractures (seven trials, 10,376 participants, RR 0.87, 95% CI 0.78 to 0.97), but there was no evidence of effect of vitamin D with calcium on vertebral fractures. The effect appeared to be restricted to those living in institutional care. Hypercalcaemia was more common when vitamin D or its analogues was given compared with placebo or calcium (14 trials, 8035 participants, RR 2.38, 95% CI 1.52 to 3.71). The risk was particularly high with calcitriol (three trials, 742 participants, RR 14.94, 95% CI 2.95 to 75.61). There was no evidence that vitamin D increased gastro-intestinal symptoms (seven trials, 10,188 participants, RR (random effects) 1.03, 95% CI 0.79 to 1.36) or renal disease (nine trials, 10,107 participants, RR 0.80, 95% CI 0.34 to 1.87).
AUTHORS' CONCLUSIONS: Frail older people confined to institutions may sustain fewer hip and other non-vertebral fractures if given vitamin D with calcium supplements. Effectiveness of vitamin D alone in fracture prevention is unclear. There is no evidence of advantage of analogues of vitamin D compared with vitamin D. Calcitriol may be associated with an increased incidence of adverse effects. Dose, frequency, and route of administration of vitamin D in older people require further investigation.
维生素D及相关化合物已被用于预防骨折。
确定维生素D或其类似物单独使用或联合钙,对预防老年人骨折的效果。
我们检索了Cochrane骨、关节与肌肉创伤组试验注册库、Cochrane对照试验中央注册库(2005年第1期《Cochrane图书馆》)、MEDLINE、EMBASE、CINAHL以及文章的参考文献列表。最近一次检索时间为2005年3月。
比较维生素D或其类似物单独使用或联合钙与安慰剂、无干预措施或单独使用钙,报告老年人骨折结局的随机或半随机试验。
两位作者独立评估试验质量并提取数据。在可行的情况下,使用固定效应模型合并数据;如果相对风险存在异质性,则使用随机效应模型。
单独使用维生素D对髋部骨折(7项试验,18668名参与者,RR=1.17,95%CI为0.98至1.41)、椎体骨折(4项试验,5698名参与者,RR(随机效应)=1.13,95%CI为0.50至2.55)或任何新发骨折(8项试验,18903名参与者,RR=0.99,95%CI为0.91至1.09)均无统计学显著影响。维生素D联合钙可略微降低髋部骨折(7项试验,10376名参与者,RR=0.81,95%CI为0.68至0.96)、非椎体骨折(7项试验,10376名参与者,RR=0.87,95%CI为0.78至0.97)的发生率,但没有证据表明维生素D联合钙对椎体骨折有影响。这种效果似乎仅限于住在养老院的老年人。与安慰剂或钙相比,给予维生素D或其类似物时高钙血症更为常见(14项试验,8035名参与者,RR=2.38,95%CI为1.52至3.71)。使用骨化三醇时风险尤其高(3项试验,742名参与者,RR=14.94,95%CI为2.95至75.61)。没有证据表明维生素D会增加胃肠道症状(7项试验,10188名参与者,RR(随机效应)=1.03,95%CI为0.79至1.36)或肾脏疾病(9项试验,10107名参与者,RR=0.80,95%CI为0.34至1.87)的发生率。
对于住在养老院的体弱老年人,补充维生素D联合钙可能会减少髋部和其他非椎体骨折的发生。单独使用维生素D预防骨折的效果尚不清楚。没有证据表明维生素D类似物比维生素D更具优势。骨化三醇可能与不良反应发生率增加有关。老年人维生素D的剂量、给药频率和给药途径需要进一步研究。